MEDICAL SCIENCE

To Cite:

Alshammrie FF, Algharbi BF, Alshammari OS, Alanazi WS. Evaluation and orientation of isotretinoin side effects among a sample of Saudi population. *Medical Science* 2023; 27: e299ms3094. doi: https://doi.org/10.54905/disssi/v27i137/e299ms3094

Authors' Affiliation:

¹Assistant Professor, Department of Dermatology, College of Medicine, University of Hail, Hail, Saudi Arabia

²Medical Student, College of Medicine, University of Hail, Hail, Saudi Arabia

³Dermatology Resident, Dermatology Department, King Abdulaziz Medical City for National Guard, Riyadh, Saudi Arabia

'Corresponding author

Dermatology Resident, Dermatology Department, King Abdulaziz Medical City for National Guard, Riyadh,

Saudi Arabia

Email: drwaelalanazi1@gmail.com

Contact List

Fawwaz Freih Alshammrie fawwzf@yahoo.com
Bassam Fahad Algharbi BassamFahad908@gmail.com
Omar Saad Alshammari OmmarSaad2367@gmail.com
Wael Saleh Alanazi Drwaelanazi1@gmail.com

Peer-Review History

Received: 06 May 2023

Reviewed & Revised: 10/May/2023 to 08/July/2023

Accepted: 12 July 2023 Published: 18 July 2023

Peer-review Method

External peer-review was done through double-blind method.

Medical Science pISSN 2321–7359; eISSN 2321–7367

This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

Evaluation and orientation of isotretinoin side effects among a sample of Saudi population

Fawwaz Freih Alshammrie¹, Bassam Fahad Algharbi², Omar Saad Alshammari², Wael Saleh Alanazi^{3*}

ABSTRACT

Introduction: Acne vulgaris is a common dermatological disorder in Saudi Arabia (KSA). Severe acne can be treated more affordably with isotretinoin, but there are a number of adverse effects to be cautious of. This study aims to identify the most prevalent isotretinoin side effects among Saudi citizens and assess how well-informed Saudis are about the drug. Methods: A longitudinal cohort study will be conducted using a pre-validated and translated electronic questionnaire and direct questions will be asked to the patient by meeting them in person, contacting them via mobile or social media. Results: This study found that 26% of 3953 people used isotretinoin, with most prescriptions being done by doctors (91%). 61.2% of participants were suffering from dryness of the body, with 61.1% suffering from dry eyes and 72.4% suffering from dry lips. 37% were aware that isotretinoin can cause birth abnormalities, while 88% of respondents used contraceptive pills, intrauterine devices (IUDs) where used by 18% from the participant while in 32% participant both contraceptive pills and isolation. In 88% of respondents, isotretinoin may help prevent pregnancy, with 50% using contraceptive pills, 18% using intrauterine devices (IUDs), and 32% using both pills and isolation. Conclusions: The study found that while isotretinoin adverse effects are common throughout the world, Saudi Arabians may not be fully aware of all of the medication's possible drawbacks. An orientation programme is needed to inform the community on the potential negative effects.

Keywords: Isotretinoin, acne, Saudi population, a long-term cohort investigation, KSA

1. INTRODUCTION

Isotretinoin taken orally has proven to be a major pharmacological breakthrough for treating severe and recalcitrant cases of inflammatory acne which in one local study show it is common dermatological disease reach 65% of total sample (Alshammrie et al., 2020). Several million patients, including a subset of children, have been treated with isotretinoin. Acne can be cured or nearly cured with isotretinoin based on clinical studies and global experience. The typical Muco-cutaneous adverse effects depend on the dose and can be managed with dose adjustment and/or extra symptomatic medication. One of



the most important potential side effects that are well understood is teratogenicity (Leyden et al., 2014).

Isotretinoin use has been linked to a number of musculoskeletal adverse effects, including arthralgia, myalgia, back discomfort, symptoms of spondyloarthropathy, and sacroiliitis (Alkan et al., 2015; Baykal-Selçuk et al., 2017; Stern, 1989). In a study conducted by Baykal-Selçuk et al., (2017), 73 individuals receiving isotretinoin for moderate to severe acne vulgaris were reviewed, and each patient was questioned regarding their inflammatory back pain and musculoskeletal problems. 42.5% of the patients experienced myalgia, while 49.3% of the patient had lower-back discomfort. 8.2% of them had acute sacroiliitis as determined by a sacroiliac MRI (Baykal-Selçuk et al., 2017).

In a different trial, Tetracycline or Isotretinoin was given to two groups of people with acne vulgaris in various methods. Spondyloarthropathy symptoms were reported by 23.1% of the participants in the isotretinoin group. The 32 patients in the tetracycline group did not experience any inflammatory back pain. Only one patient with unilateral sacroiliitis was found among the 42 patients who made up the isotretinoin group. They further stressed that the complaints were brought on by the medication and that after the treatment was terminated, all of the patients' rheumatologic symptoms disappeared (Alkan et al., 2015).

Another study looked into how isotretinoin affected Achilles tendinopathy. The researchers divided 16 rats into two groups, giving the first group isotretinoin and the second group soy oil. After six weeks, the Achilles tendons were extracted and histopathologically evaluated. It was discovered that the isotretinoin group's histology and biomechanics were adversely damaged (Beytemür et al., 2018). Studies have revealed that individuals with severe acne, particularly those who are teens and young adults, experience poorer quality of life and well-being, increased psychological discomfort and social anxiety, poor self-image, loss of self-esteem, and an increase in symptoms of anxiety, melancholy, and suicidal thoughts.

Other studies have shown that people with severe acne are more prone to experience concurrent depression and other psychological issues. In a different study, three patients using isotretinoin had sad mood, loss of interest, apathy, tearfulness, suicidal ideation, and a sense of worthlessness. Their HAM-D scores ranged from 26 to 31. After they stopped the isotretinoin and they took antidepressant the HAM-D score dropped in all patients to 7-9 with significant change in mood, which indicate a strong relation between isotretinoin and psychiatric changes (Barankin and De-Koven, 2002; Byrne et al., 1998; Chu and Cunliffe, 1999).

Sebaceous gland shrinkage, increased transepidermal water loss, skin barrier malfunction, and aberrant epidermal lipid production are the causes of isotretinoin's mucocutaneous side effects. Isotretinoin long term use results in xerosis, increased skin fragility, and an increased risk of frictional injury (Beytemür et al., 2018). Several studies report increases in serum TG of 25% of patients and in serum TC of 15% of patients, while other studies report serum TG increases of 5% to 18% and serum TC increases of 6% to 32. In follow-up studies of people using oral isotretinoin, TG, TC, and transaminase levels all increased by 5% to 44%, 6% to 31%, and 3% to 11%, respectively (Alcalay et al., 2001).

Follow-up research was undertaken on 70 patients who were receiving oral isotretinoin daily doses ranging from 20 milligrammes to 80 milligrammes, according to Vieira et al., (2012). These investigators indicated a mathematically crucial raise in the average (SD) amounts of triglycerides (87.01 (48.25) compared to 105.32 (48.76) milligram/dL), AST (20.44 (6.26) compared to 24.38 (11.92) IU/L) and ALT (18.24 (8.31) compared to 23.34 (20.03) IU/L) performed before and 3 months or more after the start of giving isotretinoin orally. 11% of the individuals had TG levels above normal after taking oral isotretinoin, while 7.3% and 8.6% of participants had raised ALT levls (Vieira et al., 2012).

A study found that early on, isotretinoin had no effect on the cornea or the conjunctiva of the globe, only the meibomian glands and the conjunctiva of the eyelids. Evaporative dry eye is the cause of the patients' symptoms, according to the initial isotretinoin signs on the eyelids, especially on the meibomian glands (Karadag et al., 2020). In a research, Isotretinoin was prescribed to patients with serious acne vulgaris to see how it would affect their pulmonary function tests (PFTs) and nasal mucociliary clearance. A 4-point scale was used to grade each side effect. The mucociliary clearance was measured using the saccharin test (ST). ST and PFTs were performed on each patient prior to and during the third month of treatment. There was a total of 40 acne sufferers.

Dehydration, chapped lips, and xerosis were the most frequent negative side effects. Of the 13 persons who reported minor epistaxis, only two had bleeding that was more than 10 cc in size. Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), forced exhalation flow rate between 25% and 75% of FVC (FEF25-75), and their predicted percentage ratios were all the same before and after the third month of treatment. Treatment considerably extended the time it took for nasal clearance to occur, and there was an important association between drug dosage and mucociliary cell clearance. Isotretinoin interfered with mucociliary clearance and produced indications and symptoms of a dry nose without altering PFTs (Pile and Sadiq, 2023).

2. METHODS AND MATERIALS

Study Design

This study conducted between September 2022 to April 2023. This study is a prospective (cohort) one. The research population in Saudi Arabia comprised people of all ages. The categories were determined on account of the population's rapid uptake of isotretinoin and their frequent attendance at dermatology clinics and other clinics on account of the drug's numerous side effects. Sampling methods include anonymously approaching patients, calling them on their phones, and sending them online questionnaires.

Collection and processing of samples

This study will make use of an electronic questionnaire that has been pre-validated and translated. The questionnaire consists of four parts. The first part about the demographic data for the participant. Second part is about the isotretinoin prescription. The third section focuses mostly on the negative effects of isotretinoin, and the fourth section tests participant understanding of isotretinoin. Additionally, to ask the patient direct questions, the patient will be reached directly via phone, in-person meetings, texts, or social media platforms.

Utilising the statistical programme Statistical Package for Social Science (SPSS) version 24, the data was evaluated, coded, and then analysed. When necessary, sophisticated analysis methods like the t-test, ANOVA, and Chi-square will be employed to compare dependent and independent variables. Descriptive statistics, such as frequency and percentage for qualitative variables, mean and SD for quantitative variables, and mean and SD for qualitative variables were used to analyse the obtained data.

Ethical consideration

The University of Hail's research ethics committee gave their approval to this project. All participants gave their informed consent before participating in the research, and they were also made aware of its goals, of their right to withdraw from it at any time, and of the confidentiality and privacy of their data.

3. RESULTS

In this current study about 3953 individuals were enrolled, of whom, 75% were females, while men make up only 25% of participants; roughly 45% of participants are between the ages of 19 and 25; 24% are over 30; 18% are between the ages of 12 and 18; and 12% are between the ages of 26 and 30; the majority of participants were of Saudi nationality; just 10% of participants were from the south; 30% of participants were from the west; 26% from the north; and 19% from the middle; near to two-third of participants had university degree, the rest either completed secondary level (34%), or other certificates (8%); The bulk of participants (71%) were single (Table 1). The ongoing current study also found that most of Isotretinoin prescription was done by doctor (91%), the rest from Pharmacist, friends or their self, 29%, 3% or 2.5% respectively (Table 2).

Table 1 Participants' distribution based upon demographic characteristics N = 3953

Variable	Value	Fr	%
Gender	Male	984	24.9
Gender	Female	2969	75.1
	12 - 18	721	18.2
Age group	19 - 25	1786	45.2
in years	26 - 30	478	12.1
	> 30	968	24.5
Nationality	Saudi	3704	93.7
Nationality	Non-Saudi	249	6.3
	North	1038	26.3
	East	559	14.1
Region	Middle	740	18.7
	West	1198	30.3
	South	418	10.6
Educational	Intermediate school	103	2.6

level	Secondary school	1325	33.5
	University	2469	62.5
	Post-graduate	25	.6
	Other	31	8
Marital	Single	2818	71.3
status	Married	1135	28.7

Table 2 Participants' distribution based upon on how much, when, and who prescribed the isotretinoin they used.

Variable	Value	Fr	%
Use of	Yes	1024	26
Isotretinoin	No	2929	74
Isotreunom	Total	3953	100
	10	182	17.8
	20	476	46.5
Dosage of	30	226	22.1
Isotretinoin	40	76	7.4
used in Mgs	50	49	4.8
	60	15	1.5
	Total	1024	100
	< 1	78	7.6
Period of	1-3	290	28.3
use per	3 – 6	372	36.3
month	More than 6	284	27.7
	Total	1024	100.0
	Doctor	933	91.5
	Pharmacist	30	2.9
Who	Friends and	32	3.1
prescribe of	relatives	32	3.1
Isotretinoin	My self	25	2.5
	alone	25	2.5
	Total	1020	100.0

About 61% of participants were suffering from complete dryness of the body; 61% were suffering from dry eyes; 72% were suffering from dry lips (Table 3). About 13% of participants were suffering from skin diseases such as eczema, 28% having redness or itching of the skin; 41% experiencing hair loss while you were using Isotretinoin; 36% suffered from changes in the psychological state or depression and about 11% of participants noticed a rise in liver enzymes after the lab tests (Table 4).

Table 3 Participants' distribution based upon whether they experience complete body, eye, or lip dryness

Variable	Value	Fr	%
Suffering from	Yes	622	61.2
complete	No	181	17.8
dryness of the	Maybe	214	21.0
body	Total	1017	100.0
	Yes	624	61.1
Suffered from	No	269	26.3
dry eyes	Maybe	128	12.5
	Total	1021	100.0
Suffer from dry	Yes	733	72.4
lips	No	173	17.1

Maybe	107	10.6
Total	1013	100.0

Table 4 Participants' distribution based upon those who have hair loss and skin conditions, changes in the psychological state or depression, or a rise in liver enzymes

Variable	Value	Fr	%
Coffeein Commelia	Yes	134	13.2
Suffering from skin	No	833	81.9
diseases such as	Maybe	50	4.9
eczema	Total	1017	100.0
	Yes	286	28.0
Having redness, or	No	639	62.6
itching of the skin	Maybe	95	9.3
	Total	1020	100.0
E	Yes	421	41.4
Experiencing hair	No	394	38.7
loss while you were using Isotretinoin	Maybe	202	19.9
using isotremion	Total	1017	100.0
Suffered from	Yes	366	35.9
changes in the	No	422	41.4
psychological state	Maybe	231	22.7
or depression	Total	1019	100.0
Noticed a rise in	Yes	111	10.9
	No	760	74.5
liver enzymes after the lab tests	Maybe	149	14.6
the lab tests	Total	1020	100.0

About 23% of participants had had gastrointestinal symptoms; 42% suffered from back, joint or bone pain; 40% noticed fatigue and lethargy while using Isotretinoin; 28% had a headache and 18% experienced dizziness or nausea (Table 5). Only 19% of participants' women mentioned that menstrual cycle affected while using Isotretinoin, while 14% of omen noticed an increase in hair growth on the body (Table 6).

Table 5 Participants' distribution based upon whether they experience stomach tremors, back, joint or bone pain, fatigue, headache, dizziness or nausea

Variable	Value	Fr	%
Had	Yes	232	22.9
	No	644	63.6
gastrointestinal symptoms	Maybe	137	13.5
symptoms	Total	1013	100.0
Caefforna d'Anoma	Yes	428	42.0
Suffered from back, joint or bone pain	No	451	44.3
	Maybe	140	13.7
	Total	1019	100.0
Noticed fatigue	Yes	404	39.7
and lethargy	No	432	42.4
while using	Maybe	182	17.9
Isotretinoin	Total	1018	100.0
Had a headache	Yes	284	28.0
Tiau a fieadactie	No	541	53.4

	Maybe	189	18.6
	Total	1014	100.0
Experienced dizziness or nausea	Yes	182	18.0
	No	697	68.9
	Maybe	132	13.1
	Total	1011	100.0

Table 6 Participants' distribution based upon effects of using Isotretinoin for woman

Variable	Value	Fr	%
For women: Was your	Yes	164	18.5
menstrual cycle	No	587	66.3
affected while using	Maybe	134	15.1
Isotretinoin	Total	885	100.0
For women: Noticed an increase in hair growth on the body	Yes	123	13.7
	No	638	71.1
	Maybe	136	15.2
	Total	897	100.0

85% of interviewees have heard of acne; Isotretinoin is used to treat acne, according to 66% of people; 41% are knowledgeable about the dangers of isotretinoin; 56% are aware that the body becomes entirely dry while using isotretinoin; Knowing that isotretinoin can cause dry eyes, 46%; compared to 26% who are aware, 76% of persons do not wear eyeglasses while taking isotretinoin. 45% are aware that testing liver enzymes and cholesterol levels is required before using isotretinoin; 31% are aware that isotretinoin elevates liver enzymes; 34% of you are aware that isotretinoin can lead to mental health issues including depression; 38% and 18% of people are aware that isotretinoin causes skin irritation and redness, respectively (Table 7).

Table 7 Participants are arranged according to how well they comprehend how to use isotretinoin and its drawbacks.

Variable	Value	Fr	%
D	Yes	2466	84.6
	No	115	3.9
Do you know what acne is?	Maybe	334	11.5
	Total	2915	100.0
	Yes	1933	66.2
Do you know that acne is	No	706	24.2
treated with Isotretinoin?	Maybe	280	9.6
	Total	2919	100.0
De seed les essents et	Yes	1185	40.6
Do you know what	No	1351	46.3
isotretinoin's negative effects are?	Maybe	384	13.2
are:	Total	2920	100.0
De contract that	Yes	1626	55.6
Do you know that	No	1107	37.9
Isotretinoin causes complete dryness of the body?	Maybe	191	6.5
dryness of the body!	Total	2924	100.0
	Yes	1339	45.9
Do you know that	No	1388	47.6
Isotretinoin causes dry eyes?	Maybe	188	6.4
	Total	2915	100.0
Do you know that wearing	Yes	754	25.9
eyeglasses is not suggested	No	1949	67.0

when taking isotretinoin?	Maybe	207	7.1
	Total	2910	100.0
Do you know that it is	Yes	1297	44.6
compulsory to check liver	No	1298	44.6
enzymes and lipid before	Maybe	316	10.9
using Isotretinoin?	Total	2911	100.0
De su la su de l	Yes	896	30.8
Do you know that	No	1681	57.8
Isotretinoin causes an increase in liver enzymes?	Maybe	333	11.4
increase in liver enzymes:	Total	2910	100.0
Do you know that	Yes	997	34.4
Isotretinoin causes	No	1575	54.3
depression and mental	Maybe	327	11.3
health disorders?	Total	2899	100.0
	Yes	521	18.0
Do you know that	No	2030	70.0
Isotretinoin causes eczema?	Maybe	351	12.1
	Total	2902	100.0
Do seed los estables	Yes	1117	38.4
Do you know that Isotretinoin causes skin	No	1429	49.1
	Maybe	365	12.5
irritation and redness?	Total	2911	100.0

Table 8 Distribution of participants' woman according to Isotretinoin use and its side effects to birth, pregnancy and their practices for preventing pregnancy

Variable	Value	Fr	%
	Yes	1070	36.7
Are you aware that Isotretinoin causes	No	1472	50.5
birth defects?	Don't know	370	12.7
	Total	2912	100.0
If you are married and take Isotretinoin, is	Yes	101	12.0
pregnancy occurs during or shortly after	No	746	88.0
using Isotretinoin?	Total	847	100.0
	Contraceptive pills	315	50.0
If you are married, how many methods	Intrauterine devices (IUDs)	109	18.0
did you use to prevent pregnancy?	Contraceptive pills and isolation	200	32.0
	Total	624	100.0

Among participants, just 37% were aware that isotretinoin causes birth abnormalities, whereas 50% were ignorant of this fact; 88% mentioned that use of Isotretinoin may prevent pregnancy occurrence; for preventing pregnancy or family planning, about 50% used contraceptive pills, 18% used intrauterine devices and 32% used both contraceptive pills and isolation (Table 8).

4. DISCUSSION

We discovered that while the adverse effects of isotretinoin in our trial were comparable to those in other studies, there was significantly less awareness of the adverse effects than in the other studies. For instance, more than fifty percent of the participants were not aware that it is not advisable to use isotretinoin while pregnant. When compared to other techniques for managing acute forms of acne, isotretinoin is more affordable for treating people with acute acne (Bagatin et al., 2020). Consumers need to know that it has been demonstrated to have several major negative consequences, including teratogenic ones (Layton, 2009; Pile and Sadiq, 2023).

Therefore, the current study— first of its sort in the region of the north— assessed female acne patients' awareness of the usage of isotretinoin and its negative effects. According to this study, 26% of participants used isotretinoin on a regular basis. This result was lower than that of a previous study by Alshaalan, (2022), which revealed that 32% of individuals used it on a regular basis. The current study also found that most of Isotretinoin prescription was done by doctor (91%), the rest from pharmacist, friends or their self, 29%, 3% or 2.5% respectively. Our results are in line with a few previous KSA research (Albadr et al., 2019; Bakheet et al., 2020).

These ecological findings point to the necessity for SFDA-PPP awareness-raising programmes beyond consumers (acne patients taking isotretinoin), as well as an improvement in community chemists' understanding of isotretinoin policy (Rashid et al., 2020). Our study also found that about 61% of participants were suffering from complete dryness of the body; 61% were suffering from dry eyes; 72% were suffering from dry lips. Our results are consistent with earlier research done in the KSA and other parts of the world (Kara-Polat et al., 2020; Tugrul-Ayanoglu et al., 2019; Younis and Al-Harbi, 2019).

The majority of participants in this study (85%) are aware of what acne is; The use of isotretinoin to treat acne is known to 66% of people; 41% are aware of the risks associated with isotretinoin; 56% are aware that isotretinoin causes the body to become completely dry; 46% are aware that isotretinoin can result in dry eyes; 26% are aware that wearing eyeglasses while taking isotretinoin is prohibited, whereas 67% are unaware of this; 45% are aware that testing liver enzymes and cholesterol levels is required before using isotretinoin; 31% are aware that isotretinoin elevates liver enzymes; 34% you know that Isotretinoin causes depression and mental health disorders; 18% know that Isotretinoin causes eczema and 38% know that Isotretinoin causes skin irritation and redness. These findings diverge from those of another study by Younis and Al-Harbi, (2019).

The study's final findings showed that just 37% of participants knew that isotretinoin causes birth abnormalities; Isotretinoin use may help prevent pregnancy, according to 88% of respondents; for preventing pregnancy or family planning, about 50% used contraceptive pills, 18% used intrauterine devices and 32% used both contraceptive pills and isolation. Our findings are align with previous studies conducted (Al-Harbi, 2010).

5. CONCLUSION

The goal of the current study was to determine if female acne patients in the reproductive age range were aware of the uses, precautions, and side effects of isotretinoin, particularly its teratogenic unfavourable effects. Therefore, it is essential to increase the understanding of female acne sufferers through health promotion activities, notably thorough teaching about the teratogenic consequences of isotretinoin must be offered. We discovered that the participants had a poor level of awareness about SFDA-PPP operations.

We also revealed that nearly a third of the engaged participants did not get the SFDA-PPP guidelines on pregnancy tests and suggested methods of contraception. The appropriate authorities must therefore carry out initiatives to raise public awareness of the SFDA-PPP and its activities. All females in the reproductive age range, including acne sufferers, should be the target audience for these efforts. The current study also aimed to investigate how patient characteristics affect patients' knowledge of dangers. The current study's findings indicate the need for more research including the two other SFDA-PPP stakeholders, chemists and doctors.

Authors' contribution

Each author contributed to the data analysis and interpretation, and they all contributed to the final draft's critical review and approval. They are also each accountable for the manuscript's content and similarity score.

Ethical approval

This study was approved by the research ethic committee, University of Hail, Saudi Arabia (H-2023-127).

Authors' Contributions

All authors share in analyzed and interpreted data, also they have critically reviewed and approved the final draft and are responsible for the content and similarity index of manuscript.

Funding

This study has not received any external funding.

Conflict of interest

The authors declare that there is no conflict of interests.

Data and materials availability

All data sets collected during this study are available upon reasonable request from the corresponding author.

REFERENCES AND NOTES

- Albadr T, Alruhaimi D, Cahusac P, Rohra D. Knowledge and use of isotretinoin in Saudi female college students: Cross -sectional study. J Dermatol Dermatol Surg 2019; 23:7 6. doi: 10.4103/jdds.jdds_2_19
- Alcalay J, Landau M, Zucker A. Analysis of laboratory data in acne patients treated with isotretinoin: Is there really a need to perform routine laboratory tests? J Dermatolog Treat 2001; 12(1):9-12. doi: 10.1080/095466301750163509
- 3. Al-Harbi M. Concerns and awareness of acne patients about isotretinoin in Qassim region of Saudi Arabia. Int J Health Sci (Qassim) 2010; 4(1):47-51.
- Alkan S, Kayiran N, Zengin O, Kalem A, Kimyon G, Kilinc EO, Pehlivan Y, Kirtak N, Onat A M, Kisacik B. Isotretinoininduced Spondyloarthropathy-related Symptoms: A Pro spective Study. J Rheumatol 2015; 42(11):2106-2109. doi: 10. 3899/jrheum.150013
- Alshaalan ZM. Knowledge on the Use of Isotretinoin and Its Side Effects and Awareness towards Saudi FDA-Pregnancy Prevention Program among the Female Acne Patients: A Northern Saudi Study. Medicina (Kaunas) 2022; 58(11):1609. doi: 10.3390/medicina58111609
- Alshammrie FF, Alshammari R, Alharbi RM, Khan FH, Alshammari SK. Epidemiology of Acne Vulgaris and Its Association with Lifestyle Among Adolescents and Young Adults in Hail, Kingdom of Saudi Arabia: A Community-Based Study. Cureus 2020; 12(7):e9277. doi: 10.7759/cureus.9 277
- Bagatin E, Costa CS, Rocha M, Picosse FR, Kamamoto CSL, Pirmez R, Ianhez M, Miot HA. Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermato logy. An Bras Dermatol 2020; 95 Suppl 1(Suppl 1):19-38. doi: 10.1016/j.abd.2020.09.001
- Bakheet KMA, Alghanemi RG, Alsiyoufi AM, Abduljabbar M, Hariri J. Females' Knowledge and Use of Isotretinoin (Roaccutane) in the Western Region of Saudi Arabia. Cureus 2020; 12(12):e12148. doi: 10.7759/cureus.12148
- 9. Barankin B, De-Koven J. Psychosocial effect of common skin diseases. Can Fam Physician 2002; 48:712-716.
- Baykal-Şelçuk L, Aksu-Arıca D, Baykal-Şahin H, Yaylı S, Bahadır S. The prevalence of sacroiliitis in patients with acne vulgaris using isotretinoin. Cutan Ocul Toxicol 2017; 36(2):1 76-179. doi: 10.1080/15569527.2016.1237521
- 11. Beytemür O, Yüksel S, Tetikkurt ÜS, Genç E, Olcay E, Güleç A. Isotretinoin induced achilles tendinopathy: Histopatho logical and biomechanical evaluation on rats. Acta Orthop

- Traumatol Turc 2018; 52(5):387-391. doi: 10.1016/j.aott.2018. 06.006
- 12. Byrne A, Costello M, Greene E, Zibin T. Isotretinoin therapy and depression Evidence for an association. Ir J Psychol Med 1998; 15(2):58-60. doi: 10.1017/S0790966700003530
- 13. Chu A, Cunliffe WJ. The inter-relationship between isotretinoin/acne and depression. J Eur Acad Dermatol Ven ereol 1999; 12(3):263. doi: 10.1111/j.1468-3083.1999.tb01042.x
- Karadag R, Karadag AS, Ozlu E, Oguztuzun S, Simsek GG, Esmer O, Onder S, Bilgili SG. Effects of Different Doses of Systemic Isotretinoin on Eyes: A Histopathological and Immunohistochemical Study in Rats. Cornea 2020; 39(5):621-627. doi: 10.1097/ico.00000000000002229
- 15. Kara-Polat A, Akin-Belli A, Ergun EZ, Manav-Bas V, Erdil D, Koku-Aksu AE, Gurel MS. Knowledge levels and concerns about oral isotretinoin treatment in the parents of adolescent acne patients. Dermatol Ther 2020; 33(4):e13669. doi: 10.1111/dth.13669
- 16. Layton A. The use of isotretinoin in acne. Dermatoendo crinol 2009; 1(3):162-169. doi: 10.4161/derm.1.3.9364
- 17. Leyden JJ, Del-Rosso JQ, Baum EW. The use of isotretinoin in the treatment of acne vulgaris: Clinical considerations and future directions. J Clin Aesthet Dermatol 2014; 7(2 Suppl):S3-S21.
- 18. Pile HD, Sadiq NM. Isotretinoin. In Stat Pearls (Internet). Stat Pearls Publishing 2023.
- Rashid ZA, Al-Tabakha MM, Alomar MJ. Proper Counseling and Dispensing of Isotretinoin Capsule Products by Community Pharmacists in UAE: A Simulated Patient Study. Clin Cosmet Investig Dermatol 2020; 13:405-414. doi: 10.2147/ccid.s256302
- 20. Stern RS. When a uniquely effective drug is teratogenic. The case of isotretinoin. N Engl J Med 1989; 320(15):1007-1009. doi: 10.1056/nejm198904133201510
- 21. Tugrul-Ayanoglu B, Demirdag HG, Yalici-Armagan B, Bezirgan O. Perceptions about oral isotretinoin treatment. Dermatol Ther 2019; 32(3):e12873. doi: 10.1111/dth.12873
- 22. Vieira AS, Beijamini V, Melchiors AC. The effect of isotretinoin on triglycerides and liver aminotransferases. An Bras Dermatol 2012; 87(3):382-387. doi: 10.1590/s0365-05962 012000300005
- 23. Younis NS, Al-Harbi NY. Public Understanding and Awareness of Isotretinoin Use and Safety in Al-Ahsa, Eastern Saudi Arabia. Ther Innov Regul Sci 2019; 53(5):618-6 22. doi: 10.1177/2168479018807677